21 CFR 50.20 is the FDA regulation that bars any investigator from involving a person in FDA-regulated research without first obtaining legally effective informed consent from the subject or the subject’s legally authorized representative. The rule sits at the front of Part 50 and sets four requirements in a single paragraph: consent must be voluntary, the person must have enough time to decide, the information must be understandable, and the consent may not include any language that waives the subject’s legal rights or releases the investigator, sponsor, or institution from liability for negligence.1eCFR. 21 CFR 50.20 – General Requirements for Informed Consent
Everything else in Part 50 builds on this section. The specific disclosures a form has to contain live in § 50.25, documentation lives in § 50.27, and three narrow exceptions live in §§ 50.22, 50.23, and 50.24. But 50.20 is the operative rule: if it is not satisfied, nothing further matters, because the consent is not legally effective and the subject cannot be enrolled.
The Four Core Requirements
Read plainly, the section imposes four conditions on every consent interaction.
First, consent must be legally effective. That means it comes from the subject, or from a legally authorized representative if the subject cannot provide it themselves, and it meets whatever formal requirements apply under state and local law.
Second, the investigator must seek consent under circumstances that give the prospective subject sufficient opportunity to consider whether or not to participate. A signature obtained in a rushed moment, or during an acute medical episode where the person has no real time to weigh the decision, does not satisfy this.
Third, those same circumstances must minimize the possibility of coercion or undue influence. This is a design requirement for the consent conversation itself, not just a prohibition on obvious pressure.
Fourth, the information must be in language understandable to the subject. This applies whether consent is written or oral, and it covers both the words used and the language they are written in.2eCFR. 21 CFR Part 50 – Protection of Human Subjects
What Voluntary Really Means
The regulation treats coercion and undue influence as two separate problems. Coercion involves a credible threat of harm, such as suggesting a patient will lose access to care if they refuse to enroll. Undue influence is more subtle: an excessive or inappropriate reward that clouds a person’s judgment about the risks. Either one can invalidate consent even when the paperwork is spotless.
Payment to subjects is the most common place undue influence shows up. The FDA treats payment as a recruitment incentive, not as a benefit that offsets research risk. IRBs review both the amount and the timing. Credit for payment should accrue as the study progresses rather than be contingent on completing the whole thing, because a large completion bonus can effectively trap a subject who wants to withdraw. A modest completion bonus is acceptable only if the IRB judges it small enough that a subject who wanted to leave would still feel free to do so.3Food and Drug Administration. Payment and Reimbursement to Research Subjects
Reimbursement for reasonable travel, parking, and lodging does not raise undue-influence concerns. Anything above out-of-pocket reimbursement does, and the full payment schedule has to appear in the consent document itself so the subject knows what they are being offered before they agree.
No Exculpatory Language, Ever
50.20 closes with an absolute prohibition: no informed consent, whether oral or written, may include any exculpatory language through which the subject is made to waive or appear to waive any legal rights, or releases or appears to release the investigator, the sponsor, the institution, or its agents from liability for negligence.1eCFR. 21 CFR 50.20 – General Requirements for Informed Consent
In practical drafting, that rules out phrases like “I waive all claims arising from this study,” “the sponsor assumes no liability for injuries,” or “by signing this form, you agree not to hold the institution responsible.” If an IRB catches exculpatory wording, the form fails review and enrollment cannot start until it is fixed. Any consent that was obtained using a document containing such wording is treated as legally ineffective.
The line the rule draws is between informing and limiting. A consent form is allowed to describe what medical treatment will be provided if a research-related injury occurs, who will pay for it, and where the subject can go for more information. What it cannot do is use that description to shrink the subject’s right to seek additional compensation through other legal channels. Sponsors sometimes draft language that sounds informational but functions to discourage claims; that language fails the standard.
Understandable Language
The requirement that information be “in language understandable to the subject” reaches further than many investigators expect, because it covers two different issues at once.
One is reading level. Most IRBs target roughly an eighth-grade reading level for consent documents. Achieving that in a form describing pharmacokinetics or a surgical implantation procedure is genuinely hard, and the standard is meant to push investigators to replace jargon with plain descriptions wherever they can. A form full of terms a typical subject cannot parse fails the 50.20 standard no matter what language it is written in.
The other is the actual language spoken. If a subject’s primary language is not English, the investigator has to provide a translated consent form or use a qualified interpreter. The FDA expects translated documents to faithfully reflect the original without omissions or added interpretation. Translations should be reviewed and approved by the IRB before use, and each translation must correspond to the specific version of the source document so subjects do not receive outdated material.
When Someone Else Can Consent
Where a subject cannot provide their own consent, 50.20 allows a legally authorized representative to consent on their behalf. Section 50.3 defines that representative as an individual or judicial body authorized under applicable law to consent to the subject’s participation in research procedures.4eCFR. 21 CFR 50.3 – Definitions
Who actually qualifies varies by jurisdiction. In some states, a parent or legal guardian holds this authority automatically. In others, a healthcare power of attorney is required. Investigators have to verify the representative’s status under the law of the jurisdiction where the research takes place rather than accept a claim of authority at face value. Getting this wrong is not just an ethical problem; it makes the consent legally ineffective under 50.20 and can jeopardize the entire dataset.
Capacity to consent is a separate question from legal competence. The ability to understand the choices being presented, appreciate the consequences of each, and communicate a decision is protocol-specific: a person might have capacity to consent to a low-risk observational study but lack capacity to consent to a high-risk interventional trial. Someone judged legally incompetent to manage their finances may still retain capacity to make a meaningful decision about research. A legally competent adult in acute confusion may temporarily lack it. And regardless of any formal assessment, an objection or resistance from the subject at any point must be treated as refusal and honored immediately.
The Three Narrow Exceptions
Outside three specific provisions, the consent requirement in 50.20 is absolute. The exceptions are worth knowing because they are frequently misunderstood as broader than they are.
Section 50.22 lets an IRB waive or alter consent for minimal-risk research where obtaining standard consent is not practicable, provided the waiver will not adversely affect the subjects’ rights or welfare.5eCFR. 21 CFR 50.22 – Exception from Informed Consent for Minimal Risk Clinical Investigations
Section 50.23 covers individual emergency use. Consent can be waived only when the investigator and an independent physician both certify in writing that the subject cannot communicate or provide consent, there is no time to reach a representative, and no approved alternative offers an equal or greater chance of saving the subject’s life. In extreme urgency the investigator can proceed and have the determination reviewed within five working days, but the documentation still has to reach the IRB within that window.6eCFR. 21 CFR 50.23 – Exception from General Requirements
Section 50.24 covers planned emergency research: whole protocols designed to study treatments for life-threatening conditions where existing options are unproven or inadequate. The IRB may approve enrollment without individual consent, but only after finding that subjects will be unable to consent because of their condition, the intervention must happen before a representative can be reached, eligible individuals cannot be identified in advance, and participation offers a prospect of direct benefit. Studies under 50.24 also require community consultation before the study begins and public disclosure of the plans, risks, and results afterward.7eCFR. 21 CFR 50.24 – Exception from Informed Consent Requirements for Emergency Research
Nothing outside those three provisions relieves an investigator of the 50.20 obligation. Convenience, tight enrollment timelines, and sponsor pressure are not exceptions.
What Happens When 50.20 Is Violated
The FDA has real enforcement tools for consent failures, and it uses them at more than one level.
At routine bioresearch monitoring inspections, FDA investigators document violations on Form FDA 483. Informed consent deficiencies are among the most commonly cited observations.8U.S. Food and Drug Administration. Inspection Observations
When violations are more serious, the FDA issues Warning Letters. One 2026 letter to a clinical investigator stated that “failure to obtain informed consent before conducting study-related procedures jeopardizes the rights, safety, and welfare of subjects by denying them an opportunity to fully assess the risks and benefits of their participation,” and gave the investigator 15 business days to respond, with further regulatory action possible if the response was inadequate.9U.S. Food and Drug Administration. Clinical Investigators – Warning Letters
The most severe administrative consequence is investigator disqualification. The FDA may initiate proceedings against any investigator who has repeatedly or deliberately failed to comply with regulatory requirements. A disqualified investigator can no longer receive investigational drugs, biologics, or devices, and cannot conduct any clinical investigation supporting an FDA application. The process starts with a formal notice and opportunity to explain, moves to an informal hearing before a presiding officer if the explanation is not accepted, and ends with a determination by the Commissioner.10U.S. Food and Drug Administration. Clinical Investigators – Disqualification Proceedings
Consent failures can also reach the product. Federal regulations allow the FDA to refuse to file a new drug application, refuse to approve it, or withdraw an existing approval if the clinical investigations were not conducted in compliance with Part 50’s informed consent requirements. The agency has stated it can reject studies where informed consent was not obtained even when the scientific validity of the data is not in question.11Food and Drug Administration. Protection of Human Subjects – Informed Consent
That is the practical weight behind a short paragraph of regulation. Fail 50.20 and the individual enrollment is invalid, the site risks a Warning Letter or worse, and the sponsor’s application can be rejected on the strength of the consent problem alone.